Erasca, Inc.

Stage 3 · Topping · week 5

As of Oct 22, 2026, Erasca is in Stage 3, the topping phase, now in week 5 (since Sep 23, 2026). It closed at $14.04, 37.5% below its 52-week high and below its 200-day average, which is rising.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. More about the company

$14.04

-0.64% today

$4.9B · Mid cap

Market Neutral — Fading

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is ERAS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 28w

S2 17w

S4 20w

S1 15w

S2 33w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 28w → S1 11w → S4 3w → S2 17w → S3 4w → S2 2w → S3 3w → S2 3w → S3 3w → S4 20w → S1 15w → S2 33w → S3 8w → S2 10w → S3 4w current

Total tracked: 165 weeks across 15 stage runs.

ERAS among Biotechnology7th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%

vs 52W High

-37.5%

$2.20 lo$22.47 hi

37.5% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 5

1w13w26w

Week 5, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-4.8%

200 DMA: $14.75 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.50x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+0.7%

-26.5%

-37.5%

YTD

+291.1%

+489.9%

Scan Membership

Breakout Watch

Latest: 2024-12-16

3 appearances in last 60 days. First seen: 2024-06-05.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 5 · Vol 0.50x

2026-10-21S3

Wk 5 · Vol 0.62x

2026-10-20S3

Wk 4 · Vol 0.91x

2026-10-19S3

Wk 4 · Vol 0.93x

2026-10-16S3

Wk 4 · Vol 1.58x

2026-10-15S3

Wk 4 · Vol 1.94x

2026-10-14S3

Wk 4 · Vol 1.09x

2026-10-13S3

Wk 3 · Vol 1.23x

2026-10-12S3

Wk 3 · Vol 1.00x

2026-10-09S3

Wk 3 · Vol 1.85x

2026-10-08S3

Wk 3 · Vol 2.34x

2026-10-07S3

Wk 3 · Vol 0.94x

Moving averages & range

50 DMA

$15.85

200 DMA

$14.75

52W High

$22.47

52W Low

$2.20

5D Low

$13.39

Resistance levels (recent highs)

20d High

$16.03

60d High

$19.49

120d High

$21.26

250d High

$22.47

Next resistance

+14.2%

to 20d High

ROE

-78.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 12.1

Erasca: quick answers

What stage is Erasca in?

As of Oct 22, 2026, Erasca (ERAS) is in Stage 3, the topping phase. It entered Stage 3 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Erasca in an uptrend?

Its uptrend has stalled. Erasca is in Stage 3, the topping phase that follows an advance. It trades 4.8% below its 200-day average, which is rising.

How far is Erasca from its 52-week high?

Erasca closed at $14.04 on Oct 22, 2026, 37.5% below its 52-week high of $22.47. Its 52-week low is $2.20.

How has Erasca performed over the past year?

As of Oct 22, 2026, Erasca is up 489.9% over the past year and up 291.1% so far in 2026.

Which sector and industry is Erasca in?

Erasca is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.